3.3 Escuela
3.3.4 Relación Escuela – Familia: elementos claves
Based on the findings of this study, the following recommendations are put forward as possible strategies for improving level of adherence among hypertensive patients.
1. Treatment protocols and guidelines for anti-hypertensive regimen must be developed and implemented.
2. Effective communication and counseling techniques for physicians and pharmacy staff should be developed through regular in-service training.
3. Physicians should educate their first time diagnosed hypertensive patients about their disease conditions and the importance of adherence to treatment.
4. Physicians should consider the financial status of their patients in prescribing antihypertensive drugs to enable affordability and hence adherence.
5. Physicians should endeavour to prescribe an effective, inexpensive medication with minimal side effects as this will improve patient’s adherence considerably.
6. Further research using another validated tool to measure adherence in patients with hypertension is recommended.
REFERENCES
1. Bloomfield P, Bradbury A, Grubb NR, Newby DE. Cardiovascular disease-Hypertension.
In: Boon NA, Colledge NR, Walker BR, Hunter JA editors. Davidson`s principles &
practice of Medicine. 20thed.Elsevier Ltd, Churchill Livingstone. 2006: p 551, 608-615.
2. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004;
42(2): 102-109.
3. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002; 40:794-811.
4. Mahoney JJ. Value-based benefit design: Using a predictive modeling approach to improve compliance. J. Manag Care Phar. 2008; 14(6): S3-S8.
5. Gonzalez J, Noga M. Medication Therapy Management.JMCP.2008; 14(6):S8- S11.
6. Bokhour, B.G., et al., How do providers assess antihypertensive medication adherence in medical encounters? Journal of general internal medicine, 2006. 21(6): p. 577-583.
7. Haynes RB, McDonald H, Garg AX, Montague P: Interventions for helping patients to follow prescriptions for medications (Review). Cochrane Database Syst Rev CD000011, 2002.
8. Sabate E. Adherence to long-term therapies: evidence for action. Geneva, World Health Org. Available athttp://www.who.int/chp/knowledge/publications/adherence_report/en/
index.html. Accessed November 18, 2008.
9. American Diabetes Association. Direct and indirect costs of diabetes in the United States.
Available at: www.diabetes.org/diabetes-statistics/cost-of-diabetes-inus. jsp. Accessed on November 20, 2008.
10. Cramer J. Medicine partnerships. Heart. 2003; 89: 19-21..
11. Halpern MT. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006; 47:1039–48.
12. Hassan NB, Hasanah CI, Foong K, Naing L, Awang R. Identification of psychosocial factors of noncompliance in hypertensive patients. J Hum Hypertens. 2006; 20: 23–29.
13. Chobanian AV, Bakris GL, Black HR. The Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC VII report. JAMA 2003; 289(19): 2560-2572.
14. Belue R, Okoror TA, Iwelumor J, Taylor KD, Degboe AN, Agyemang C et al. An overview of cardiovascular risk factors in sub-Saharan Africa. A socio-cultural perspective. Global Health [serial.online] 2009; 5(10) 12. Available @ http://www.idf.org/home retrieved on 27/12/2011
15. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: WHO Press; 2009.p 9-12.
16. Falase AO, Akinkugbe OO. The Cardiovascular system-Blood pressure. In: A Compendium of Clinical Medicine 3rd ed. Spectrum Books Ltd Ibadan, Nigeria. 2007: p 18.
17. Kearney PM, Whelton M, Reynolds K,Muntner P, ,Whelton PK. Global burden of hypertension- analysis of worldwide data. Lancet 2005; 365: 217-223.
18. Boutayeb A, Boutayeb S. The burden of non-communicable diseases in developing countries. International Journal for Equity in Health 2005. 4:2.
19. Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
20. Salako BL, Ayodele OE, Kadiri S, Arije A. Assessment of blood pressure control in a black African population. Cardiol Trop. 2002; 9: 3-6
21. Opie LH, Seedat YK. Hypertension in Sub-Saharan African populations. Circulation. 2005;
112: 3562-3568.
22. Baigent C. the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267–78.
23. Cushman WC. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich) 2006;8:865–72.
24. Mant J, Mcmanus RT. Does it matter whether patients take their antihypertensive medication as prescribed? The complex relationship between adherence and blood pressure control. J Human Hypertens.2006; 20:551-553.
25. World Health Organization. Chapter xii. Hypertension and Adherence to long therapies.
Evidence for action.2003; [accessed February2012] 129 136.Available:http://www .emro.who.int/ncd/publications/adherence-report.pdf.
26. Okonofua EC, Simpson KN, Jessi A. Thearpeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertens. 2006; 47: 345-351
27. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long term persistence in statin therapy in the elderly. JAMA. 2002; 288: 455-461.
28. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available at http://www.nhlbi.nih.gov/guidelines/
hypertension/jnc7full.pdf. Assessed on January 1, 2009
29. Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring one-year compliance to antihypertension medication in Seychelles. Bulletin of the World Health Organization.2002; 80: 33-39.
30. Habtamu AH, Mesfin A. Assessments of Adherence to Hypertension Medications and Associated Factors among Patients Attending Tikur Anbessa Specialized Hospital Renal Unit, Addis Ababa, Ethiopia 2012 Inter J Nurs Sci. 2013; 3(1): 1-6
31. Okeahialam BN. Adherence and Preference Issues in Anti-hypertensive Therapy:
Experience from a Private medical Facilit y in Jos. J Med Trop 2011; 13:ll.
32. Akpa MR, Agomuoh Dl, Odia OJ. Drug Compliance Among Hypertensive patients in Port Harcourt Nigeria. Niger J Med 2005; 14:55.
33. Kabir M, lliyasu Z, Abubakar IS, Jibril M. Compliance to medication among hypertensive patients in Murtala Mohammed Specialist Hospital, Kano. Journal of Community Medicine
& Primary Health Care 2004; 16:16.
34. Hashmi SK, Afridi MB, Abbas K, Sajwani RA, Salaheen D. Factors associated with adherence to antihypertensive treatment in Pakistan. PLOS ONE 2007; [accessed 20June 2012]. 2:3. Available from: www.plosone.org.
35. Higgins, M. Adherence or compliance? World of Irish Nursing & Midwifery 2006; 14 (10):
28-29.
36. Delamater AM. Improving patient adherence. Clin Diabetes 2006; 24: 71.
37. Meichenbaum D, Turk DC. Facilitating Treatment/Adherence: A Practitioner's Guidebook.
Plenum Press, NewYork 1987.
38. World Health Organization (WHO) Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO; 2003.
39. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006, 28, 1411.
40. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al. .Medication compliance and persistence: Terminology and definitions. Value Health 2008; 11, 44.
41. Dolavich L, Sellors JW, Haynes RB, Drug Compliance. In: Rakel RE Essential Family Medicine Fundamentals and Case Studies 3rd ed. Sunders Elsevier Publishers Philadelphia 2006; p.89-100.
42. Mant J, McmanusRT.Does it matter whether patients take their antihypertensive medication as prescribed? The complex relationship between adherence and blood pressure control. J Human Hypertens.2006; 20:551-553.
43. Lahdenpera TN, Kyngas, HA. Review: compliance and its evaluation in patients with hypertension. International Journal of Clinical Nursing. 2000; 9 (6): 826-833.
44. Eisendrath SJ, Lichtmacher JE. Hypertension In: Tierney Jr. LM, McPhee SJ, Papdakis MA.editors. Current Medical Diagnosis & Treatment. 47th ed. © McGrawHill 2008: p. 897-948.
45. Burnier M (2006) Medication adherence and persistence as the cornerstone of effective anti hypertensive therapy. American Journal of Hypertension19: 1190–1196.
46. Krousel-Wood M, Thomas S, Muntner P, Morisky D (2004) Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Current Opinion in Cardiology19: 357–362.
47. Garfield FB, Caro JJ. Achieving patient buy-in long-term compliance with antihypertensive treatment. Disease Management and Health Outcomes.2000; 7 (1): 13-20.
48. Wetzels GEC, Nelemans PJ, Schouten JSAG, Wijk BLG, Prins MH. All that glitters is not gold: a comparison of electronic monitoring versus filled prescriptions-an observational study. BMC Health Services Research.2006; 6:8
49. Mengden T, Vetter H, Tousset E, Uen S. Management of patients with uncontrolled arterial hypertension: the role of electronic compliance monitoring, 24hr ambulatory blood pressure monitoring and Candesartan/HCT. BMC Cardiovascular Disorders. 2006; 6:36
50. Jambedu H.A. Adherence to anti-hypertensive medication regimens among patients attending the G.P.H.A hospital in Takoradi – Ghana. B. Pharm [Thesis]: Kwame Nkrumah University of Science and Technology; 2006.
51. Bovet, P, Burnier, M, Madeleine, G, Waeber, B &Paccaud, F. Monitoring one-year compliance to antihypertension medication in Seychelles. Bulletin of the World Health Organization 2002; 80: 33-39.
52. Lavsa SM, Holzworth A, Ansani NT. Selection of a Validated Scale for Measuring Medication Adherence. J Am Pharm Assoc. 2011; 51(1):90-94.
53. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24 (1):67-74.
54. Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res. 2008; 100:53–9.
55. Hahn SR, Park J, Skinner EP, et al. Development of the ASK-20 Adherence Barrier Survey.
Curr Med Res Opin. 2008; 24:2127–38.
56. Elm JJ, Kamp C, Tilley BC, et al. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. MovDisord. 2007; 22:822–7.
57. Afonso NM, Nassif G, Aranha AN, et al. Low-density lipoprotein cholesterol goal attainment among high-risk patients: does a combined intervention targeting patients and providers work? Am J Manag Care. 2006; 12:589–94.
58. Gao X, Nau DP. Congruence of three self-report measures of medication adherence among HIV patients. Ann Pharmacother. 2000; 34:1117–22.
59. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008; 10(5):348-54.
60. Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr. Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol. 2011;
64(3):2504.
61. Morisky DE, Ang A, Krousel-Wood MA, Ward H. Predictive validity of a medication adherence measure in an outpatient setting. Am J Manag Care. 2009; 15:59–66.
62. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in Hypertens. 2008; 10:348 –354.
63. Gabrielle KYL, Harry HX, Wang –Kirim QL, Cheung YU, Morisky DE, Martin CSW.
Determinants of Medication Adherence to Antihypertensive Medications among a Chinese Population Using Morisky Medication Adherence Scale PLoS One. 2013; 8(4): e62775.
Published online 2013 April 25. doi: 10.1371/journal.pone.0062775PMCID: PMC3636185 64. Burnier M. Medication adherence and persistence as the cornerstone of effective anti
hypertensive therapy. American Journal of Hypertension. 2006; 19: 1190–1196.
65. Krousel-Wood M, Thomas S, Muntner P, MoriskyD.Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients.
Current Opinion in Cardiology. 2004; 19: 357–362.
66. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas. 2007; 15:203–19.
67. Svarstad BL, Chewing BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;
37:113–24.
68. Krass I, Taylor SJ, Smith C, Armour CL. Impact on medication use and adherence of Australian pharmacists' diabetes care services. J Am Pharm Assoc. 2005; 45:33–40.
69. Rickles NM, Svarstad. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm. 2007; 3:363–77.
70. Cook CL, Wade WE, Martin BC, Perri M. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc. 2005;
45:151–9.
71. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000; 15:90–6.
72. Krousel-Wood M, Muntner P, Jannu A, et al. Reliability of medication adherence measure in an outpatient setting. Am J Med Sci. 2005; 330:128–33.
73. Nguyen GC, Laveist TA, Harris ML, et al. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis.
2009; 15:1233– 9.
74. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000; 42:241–7.
75. Fialko L, Garety PA, Kuipers E, et al. A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res. 2008; 100:53–9.
76. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medications compliance. Clin Therapeutics. 2001; 23: 1296 – 1310.
77. Gabrielle K. Y. Lee,1Harry H. X. Wang,1Kirin Q. L. Liu,1Yu Cheung,2Donald E. Morisky,3 and Martin C. S. Wong Determinants of Medication Adherence to Antihypertensive Medications among a Chinese Population Using Morisky Medication Adherence Scale D.
William Cameron, Editor PLoS One. 2013; 8(4): e62775. Published online 2013 April 25 78. Inkster ME, Donnan PT, MacDonald TM, Sullivan FM, Fahey T. Adherence to
antihypertensive medication and association with patient and practice factors. Journal of Human Hypertension (2006) 20, 295–297.
79. Cokkinos DV. Adherence to antihypertensive treatment: A critical factor for blood pressure control European J Preventive Cardiology. 2005; vol. 12 (3) 243-249
80. Natarajan N, Putnam W, Aarsen VK, Beverley LK, Burge F Adherence to antihypertensive medications among family practice patients with diabetes mellitus and hypertension. Can Fam Physician 2013; 59(2): 93-100.
81. Hashmi, SK, Afridi, MB, Abbas, K, Sajwani, RA & Salaheen, D. Factors associated with adherence to antihypertensive treatment in Pakistan. PLOS ONE [Serial on line] 2007; 2:3 Available from: www.plosone.org
82. Habtamu AH, Mesfin A. Assessments of Adherence to Hypertension Medications and Associated Factors among Patients Attending Tikur Anbessa Specialized Hospital Renal Unit, Addis Ababa, Ethiopia 2012 Inter J Nurs Sci. 2013; 3(1): 1-6
83. Victoria F. Factors Associated With Poor Medication Adherence In Hypertensive Patients In Lusaka, Zambia. Medical Journal of Zambia Achives. 2012; (3).
84. Okoro RN, Ngong CK. Assessment of patient's antihypertensive medication adherence level in non-co morbid hypertension in a tertiary hospital in Nigeria. Int J Pharm Sci .2012;3(2).47-54
85. Odili VU, Oghagbon EK, Ugwa NA, Ochei UM, Aghomo OE. Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria. Trop J Pharmaceut Res 2008; Vol. 7 (2) pp. 945-952. Available online at http://www.tjpr.org 86. Ekwunife OI, Udeogaranya PO, Adibe MO. Predictors of Self Reported Adherence to
Antihypertensive Drugs in a Nigerian Population. Inter J Pharm Sci. 2010; Vol.2 (1): 23-29
87. Osamor PE, Owumi BE. Factors Associated with Treatment Compliance in Hypertension in Southwest Nigeria. J HEALTH POPUL NUTR 2011; 29(6): 619-628
88. Adeyemo A, Tayo BO, Luke A, Ogedegbe O, Durazo-Arvizu R, Cooper RS. The Nigerian antihypertensive adherence trial: a community-based randomized trial. J Hypertens. 2013;
31(1):201-7.
89. Jokisalo E, Kumpusalo E, Enlund H, Halonen P, Takala, J. Factors related to non- compliance with antihypertensive drug therapy. Journal of Human Hypertension. 2002; 16 (8): 577- 583.
90. Benson J, Britten N. Keep taking the tablets. British Medical Journal. 2003; 326:1314–1315 91. Iskedjian M, Einarson TR, MacKeigan LD. Relationship between daily dose frequency and
adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. Clin Ther.
2002; 24: 302–316.
92. Sunil K, Ameeta P, Mandlecha RH. Compliance and Adverse drug Effects of Antihypertensives in Rural India J Clin and Diagnostic Research. 2011; 5(4): 775-779.
93. Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis Hypertension. 2010; 55: 399-407.
94. Elijovich F, Laffer C. Therapeutic Advances in Cardiovascular Disease: A Role for Single-pill Triple Therapy in Hypertension. Ther Adv Cardiovasc Dis. 2009;3 (3):231-240.
95. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
JAMA 2004; 292:952-960.
96. Ponnusankar S, Surulivelrajan M, Anandamoorthy N. Assessment of impact of medication counseling on patients' medication knowledge and compliance in an outpatient clinic in South India. Patient Educ Couns. 2004; 54 - 55.
97. Osamar PE, Owumi BE. Factors Associated with Treatment/Compliance in Hypertension in Southwest Niger .J Health Popul Nutr 2011; 29: 619.
98. Palaian SAK, Chhetri M, PrabhuS, Rajan, PR Shankar. The Internet J Pharmacol 2005;
4(1): doi: 10.5580/105.
99. Schoenthaler A. Provider communication effects medication adherence in hypertensive African Americans. Patient education and counseling, 2009. 75(2): p. 185-191.
100. Safeer, R.S. and J. Keenan, Health literacy: the gap between physicians and patients.
American family physician, 2005. 72(3): p. 463-468.
101. Bokhour BG. How do providers assess antihypertensive medication adherence in medical encounters? Journal of general internal medicine, 2006. 21(6): p. 577-583.
102. Nudrat NQ. Effect of general practitioner education on adherence to antihypertensive drugs:
cluster randomized controlled trial. BMJ 2007;[cited Nov 2012] Available from doi:
http://dx.doi.org/10.1136/bmj.39360.617986.AE335
103. Amira CO, Okubadejo NU. Factors influencing non compliance with anti hypertensive drug therapy in Nigerians. Niger. Postgrad M. J. 2007; 14(4): 325-359.
104. Isezuo AS, Opera TC. Hypertension awareness among Nigerians in a Nigerian tertiary health institution. Sahel Medical Journal 2000; 3(2): 93-96
105. Krousel-Wood M, Thomasa S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients.
Curr Opin Cardiol 2004; 19: 357–362.
106. Egan BH, Lackland DT, Cutler NE. Awareness, knowledge and attitudes of older Americans about high blood pressure. Arch Intern Med. 2003; 163: 681–687.
107. Kyngas HA, Lahdenpera TN. Compliance of patients with hypertension and associated factors. Journal of Advanced Nursing.1999; 29 (4):832-839.
108. Ren XS, Kazis LE, Lee A, Zhang H, Miller DR. Identifying patient and physician characteristics that affect compliance with antihypertensive medications. Journal of Clinical Pharmacy and Therapeutics. 2002; 27( 1 ): 47-58.
109. Munger MA, Tassell BWV, Lafleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. Medscape General Medicine, 2007; 9(3): 58. Available from:
http://www.pubmedcentral.nih.htm).
110. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002; 288: 2868 – 2879.
111. Jambedu H.A. Adherence to anti-hypertensive medication regimens among patients attending the G.P.H.A hospital in Takoradi – Ghana. B. Pharm [Thesis]: Kwame Nkrumah University of Science and Technology; 2006.
112. Claxton AJ, Cramer J, Pierce C A. systematic review of the association between dose regimens and medications compliance. Clin Therapeutics. 2001; 23: 1296 – 1310.
113. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on prevention detection, evaluation and treatment of high blood pressure: the JNC 7 Report. JAMA.2003; 289(19):2560-2572.
114. Sutters M. Systemic Hypertension. In: McPhee SJ, Papadakis MA, Tierney Jr. LM editors.
Current Medical Diagnosis & Treatment. 47thed.The McGraw-Hill Co, Inc. 2008: p 370-397.
115. Bloomfield P, Bradbury A, Grubb NR, Newby DE. Cardiovascular disease-Hypertension.
In: Boon NA, Colledge NR, Walker BR, Hunter JA editors. Davidson`s principles &
practice of Medicine. 20thed.Elsevier Ltd, Churchill Livingstone. 2006: p 551, 608-615.
116. WHO-ISH Guidelines Subcommittee. 1999 WHO-1SH guidelines for the management of hypertension. J Hypertens. 1999; 17:151-83.
117. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;
21:1011-53.
118. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252.
119. Miller, H., Berra, K., & Long, J. (2009). Awareness, understanding, and treatment of previously diagnosed hypertension in baby boomers and seniors: a survey conducted by harris interactive on behalf of the preventive cardiovascular Nurses association. 12 (5), 328-334.
120. Kotchen TA. Hypertensive Vascular Disease. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hawer SL, Jameson JL et al editors. Harrison`s Principles of Internal Medicine.17th ed. The McGraw-Hill Co, Inc 2008: p1549-1562.
121. Khatib, O. Non-communicable diseases: risk factors and regional strategies for prevention and care. Eastern Mediterranean Health Journal 2004;10(6): 778-788
122. Boon NA, Fox KAA, Bloomfield P, Bradbury A: Cardiovascular Disease. In: Haslett C, Chilvers ER, Boon NA, College NR, Hunter JAA (editors), Davidson’s Principles and Practice of Medicine 19th ed. © Elsevier Science Ltd (CHURCHILL LIVINGSTONE) 2002: p 357-481.
123. World Health Organization (WHO) Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO; 2003.
124. Kearney P, Whelton, M., Reynolds, KM, Whelton P. Global burden of hypertension:
analysis of worldwide data. Lancet. 2005; 365, 217–23.
125. Ostchega Y, Yoon S, Hughes J, Louis T. (2008). Hypertension Awareness, Treatment, and Control—Continued Disparities in Adults. United States, 2005–2006 National Center for Health Statistics.
126. Adedoyin RA, Mbada CE, Balogun MO, Martins T, Adebayo RA, Akintomide A et al.
Prevalence and pattern of hypertension in a semi-urban community in Nigeria. Eur J Cardiovasc Prev Rehabil 2008; 15: 683-687.
127. Falase AO, Akinkugbe OO. The Cardiovascular system-Blood pressure. In: A Compendium of Clinical Medicine 3rd ed. Spectrum Books Ltd Ibadan, Nigeria. 2007: p 18.
128. Opie L. H, Seedat, Y. K. Hypertension in Sub-Saharan African populations. Circulation.
2005; 112, 3562-3568.
129. Sani MU, Wahab KW, Yusuf BO, Gbadamosi M, Johnson OV, Gbadamosi A. Modifiable cardiovascular risk factors among apparently healthy adult Nigerian population – a cross sectional study. BMC Res Notes [serial online]. 2010 [cited 2010 Jan 26]; 3(11): [26pages].
Available from: http://www.biomedcentral.com/1756-0500/3/11.
130. Isezuo SA, Sabir AA, Ohwovorilole AE, Fasanmade OA. Prevalence, associated factors and relationship between prehypertension and hypertension: a study of two ethnic African populations in Northern Nigeria. J Hum Hypertens. 2011; 25:224-30.
131. Kolo PM, Jibrin IYB, Sanya EO, Alkali IM, Peter Kio IB, Moronkola RK. Hypertension-Related Admissions and Outcome in a Tertiary Hospital in Northeast Nigeria. Intern J Hyperten .2012; p 6. Available at www.http://dx.doi.org/10.1155/2012/960546Research 132. Adedoyin RA, Mbada CE, Balogun MO, Martins T, Adebayo RA, Akintomide A et al.
Prevalence and pattern of hypertension in a semi-urban community in Nigeria. Eur J Cardiovasc Prev Rehabil. 2008; 15:683-7.
133. Oladapo OO, Salako L, Sodiq O, Shoyinka K, Adedapo K, Falase AO. A prevalence of cardiometabolic risk factors among rural Yoruba south-western Nigerian population: a population-based survey. Cardiovasc J Afr. 2010; 21: 26-31.
134. Omuemu VO, Okojie HO, Omuemu CE. Awareness of high blood pressure status, treatment and control in a rural community in Edo state. Niger J Clin Pract. 2007; 10(3):
208-12.
135. Ahaneku GI, Osuji CU, Anisiuba BC, Ikeh VO, Oguejiofor OC, Ahaneku JE. Evaluation of blood pressure and indices of obesity in a typical rural community in eastern Nigeria. Ann Afr Med. 2011; 10:120-6.
136. Onwubere BJC, Ejim EC, Okafor CI, Emehel A, Mbah AU, Onyia U, et al. Pattern of blood pressure indices among the residents of a rural community in South East Nigeria. Int J Hypertens [serial online]. 2011[cited 2011 Oct 10]; Article ID 621074: [6 pages]. Available from: http://www.hindawi.com/journals/ijht/2011/621074/.
137. Mbah BO, Eme PE, Ezeji J. Prevalence and Risk Factors of Hypertension Among Middle-Aged Adults in Ahiazu Mbaise Local Government Area, Imo State, Nigeria. IJBAS-IJENS Vol. 13. P 126. Available at http://www.ijens.org/Vol_13_I_01/123406-1301-7575-IJBAS-IJENS.pdf
138. Eisendrath SJ, Lichtmacher JE. Hypertension In: Tierney Jr. LM, McPhee SJ, PapdakisMA.editors. Current Medical Diagnosis & Treatment. 47th ed. © McGrawHill 2008: p. 897-948.
139. Greeff, D. An approach to preventing and treating hypertension through lifestyle modification. Professional Nursing Today. 2006; 10(5): 8-22.
140. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002; 62:443-62.
141. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomized trials. BMJ 2003; 326:1427-34.
142. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al.
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults.